iCMLf Knowledge Centre

Welcome to the iCMLf Knowledge Centre an interactive online resource providing educational content on CML patient management, options for molecular monitoring and practical considerations of BCR-ABL1 testing

Content developed by international CML experts from the iCMLf

Modules

Paediatric CML

Chaired by Professor Meinolf Suttorp and Professor Nirmalya Roy Moulik, this module outlines a comprehensive review of the treatment of paediatric CML.

Topics:

Treatment Recommendations for CML – Chronic Phase – Professeur Frédéric Millot
Treatment Recommendations in Paediatric CML Blast Phase – Dr Stephanie Sembill
Treatment Free Remission in Paediatric CML – Professor Nobuko Hijiya
Tyrosine Kinase Inhibitor Toxicity in Paediatric CML – Dr Maaike Luesink
Parenting in Children with CML – Professor Meinolf Suttorp
Management of Paediatric CML in the Resource-Constrained Setting
(coming soon)
Difference Between Adult and Paediatric CML
(coming soon)
Bone Health in Paediatric CML
(coming soon)
Predisposition and Genetic Factors in Paediatric CML
(coming soon)

Open Module

Management Practicalities

Chaired by Professor Giuseppe Saglio (Italy) and Professor Mohamed Yassin (Qatar) this module will feature topics on the practical management of CML.

Topics:

Managing intolerances – Perspectives from the real world – Dr Massimo Breccia (Italy)
Managing comorbidities – Perspectives from the real world – Dr Mohamed Yassin (Qatar):
1. Hepatitis B Reactivation
2. Managing Obesity
3. Association of Tuberculosis in patients with CML
4. Opthalmic manifestations as the initial presentation of CML
Nature and incidence of adverse events – Dr Valentín García Gutiérrez (Spain)
TKI interactions with concomitant medication – Dr Katerina Machova Polakova (Czech Republic)
Generic TKIs – Dr Jeff Lipton (Canada)
When to consider Allogenic transplantation in CML – Dr Jerry Radich (USA)

Open Module

CML Therapy

Chaired by Professor Jorge Cortes and Professor Qian Jian, this module outlines the current therapies for CML and the international guidelines supporting therapeutic decisions.

Topics:

Frontline therapy – Professor Jorge Cortes
When frontline therapy fails and beyond the second line therapy – Dr Jeff Lipton
Beyond the chronic phase – Professor Susanne Saussele
International recommendations and guidelines and how these have shifted in the last decade – Professor Andreas Hochhaus

Open Module

Treatment Free Remission

Chaired by Professor Tim Hughes and Dr Katia Pagnano, this module will outline current considerations to meet the goal of treatment free remission (TFR)

Topics:

Understanding the Biological Nature of TFR – Professor Mhairi Copland
Identifying the Best Candidates for TFR – Dr Naranie Shanmuganthan
The Ideal – when TFR can be recommended – Professor Tim Hughes & Professor Ehab Atallah
The Practical – how to implement TFR in resource constrained centres – Dr Katia Pagnano & Professor Hemant Malhotra
How to Communicate with Patients about TFR – Professor Gianantonio Rosti

Open Module

From the Laboratory – Non-clinical

Chaired by Professor Nick Cross and Dr Neelam Varma, this module will discuss current and future diagnosis and testing methods from the perspective of non-clinical scientists.

Topics:

Measurable residual disease detection in chronic myeloid leukaemia – Professor Nick Cross
Current and future techniques/trends – Professor Susan Branford
Laboratory testing in a resource constrained environment – Dr Neelam Varma
New ways to improve molecular analysis in resource constrained environments – Professor Jerry Radich

Open Module

From the Laboratory – for Clinicians

Chaired by Professor Jerry Radich and Dr Carolina Pavlovsky this module discusses current and future diagnosis and testing methods from the perspective of clinicians.

Topics:

Main laboratory studies at diagnosis – Dr Carolina Pavlovsky
Optimal test frequency for MRD – Dr Carolina Pavlovsky
Clinical data to support each treatment milestone – Dr Kendra Sweet
Essential molecular monitoring (focusing on low and middle-income countries) – Professor Jerry Radich
When BCR-ABL1 mutation testing is recommended – Assistant Professor Simona Soverini
The role of genomic analysis and panel mutation screening – Professor Michael Deininger

Open Module

This program is supported by Novartis Oncology. All content has been developed by CML experts under the guidance of Professor G. Saglio, Turin, Italy.

New Topics Phase II

The first tranche of Phase II topics are available. An outline of Phase II topics include; pregnancy and fertility in CML, pediatric CML, and next steps for CML management. If you have topics you would like to see discussed please contact us.